NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Challenges of designing & evaluating clinical trials for immunotherapies in the GBM field is nothing more and nothing less than what we have heard Dr. Liau discussing last year and what has been discussed in The Lancet journal article in Oct.

Simply put:
For a trial in a lethal disease such as GBM you just cant from an ethical standpoint maintain a placebo control arm especially when the treatment is working. In other words, you can not let the placebo die so the statistics will benefit better.

And of course that's a challenge for its new